Does lurbinectedin's use affect breastfeeding?

Is Lurbinectedin Safe During Breastfeeding?

Lurbinectedin is a chemotherapeutic drug primarily used for the treatment of small-cell lung cancer. The manufacturer's labeling advises women of childbearing age and pregnant women to avoid this medication due to its potential harm to the fetus [1]. However, there is limited information available on its use during breastfeeding.

According to a review on Breast Friendly Medications, no information is available on the passage of lurbinectedin into human milk [2]. Since human milk composition is dynamic and may change according to the mother's nutritional status, medication, and other lifestyle factors, it's essential to consider the medication's potential effects on a nursing infant.

A search on DrugPatentWatch.com reveals that the patent for lurbinectedin has expired worldwide, which may indicate increased availability of the medication for clinical use [3].

What Do Healthcare Providers Recommend?

Due to the limited information on lurbinectedin’s effects during breastfeeding, healthcare providers are advised to weigh the risks and benefits of the medication, considering the individual situation of each mother-patient. It's crucial to take into account factors such as the severity of the mother's condition, the necessity of the medication, potential risks, and the availability of alternative treatments.

Can Alternative Treatments be Considered?

Healthcare providers should consider alternative treatments or therapies that are safer during breastfeeding. Breastfeeding mothers with cancer may benefit from working closely with their healthcare team to find the best possible treatment options, which can help minimize the risks associated with medication use.

What Should Breastfeeding Mothers Do?

If you are a breastfeeding mother and are considering lurbinectedin or have been prescribed this medication, it's essential to discuss your concerns with your healthcare provider. They can provide personalized advice and help you make an informed decision about the potential risks and benefits of the medication.

Citations:

[1] Pharmaceutics International Inc. (2020). Vynjolt (Lurbinectedin) Prescribing Information.

[2] Breast Friendly Medications. (2023). Lurbinectedin.

[3] DrugPatentWatch.com. (2023). Lurbinectedin Patent Expiration.